ABSTRACT:

Despite long standing controversies about the therapeutic validity of placebo due to its administration of inert substances, placebo emerges for its efficacy to amplify the therapeutic benefits of active medical interventions through patients’ psychological beliefs and expectations. Advances in neuroimaging and utilization of hormonal agonists have elucidated underlying brain mechanisms and biochemical pathways such as the endogenous opioid systems. This research synthesizes pivotal studies on placebo effect, including Beecher’s 1995 analysis; whereas, Hróbjartsson and Gøtzsche’s 2001 meta analysis refuted its clinical significance. In-depth interaction in the assumption of additivity between placebo and active treatment as well as deep brain stimulation in Parkinson’s Disease reveals the placebo’s prominence in brain reward mechanisms. Moreover, placebo mechanisms induce significant neurotransmission in the endogenous opioid systems and several brain regions including periaqueductal gray. Further inquiries are necessitated for precision in examining the role of expectation, emotions, interactions with test administrators, as well as genetic levels.

KEYWORDS:

Placebo effect, Therapeutic benefits, Psychological beliefs, Neuroimaging, Brain mechanisms, Endogenous opioid systems, Parkinson’s Disease, Further inquiries

REFERENCES :

1) Ader, R. (1997). The role of conditioning in pharmacotherapy. In A. Harrington (Ed.), The placebo effect: An interdisciplinary exploration (pp. 138–165). Harvard University Press.
2) Adriani Nikolakopoulou, Chaimani, A., Furukawa, T. A., Theodoros Papakonstantinou, Gerta Rücker, & Schwarzer, G. (2023). When does the placebo effect have an impact on network meta-analysis results? BMJ Evidence-Based Medicine, bmjebm-112197. https://doi.org/10.1136/bmjebm-2022-112197
3) Anderson, A., & Cohen, M. S. (2013). Reducing Clinical Trial Costs by Detecting and Measuring the Placebo Effect and Treatment Effect Using Brain Imaging. Studies in HealthTechnology and Informatics, 184, 6–12. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4157941/
4) Beecher, H. K. (1955). THE POWERFUL PLACEBO. Journal of the American Medical Association, 159(17), 1602. https://doi.org/10.1001/jama.1955.02960340022006
5) Benedetti, F., Arduino, C., & Amanzio, M. (1999). Somatotopic activation of opioid systems by target-directed expectations of analgesia. The Journal of Neuroscience: The Official Journal of the Society for Neuroscience, 19(9), 3639–3648. https://pubmed.ncbi.nlm.nih.gov/10212322/
6) Chloé Pronovost-Morgan, Ido Hartogsohn, & Ramaekers, J. G. (2023). Harnessing placebo:Lessons from psychedelic science. Journal of Psychopharmacology, 37(9), 866–875.https://doi.org/10.1177/02698811231182602
7) Cleghorn, R. A., & Graham, B. F. (1950). Studies of adrenal cortical activity in psychoneurotic subjects. The American Journal of Psychiatry, 106(9), 668–672. https://doi.org/10.1176/ajp.106.9.668
8) Colagiuri, B., Schenk, L. A., Kessler, M. D., Dorsey, S. G., & Colloca, L. (2015). The placebo effect: from concepts to genes. Neuroscience, 307, 171–190. https://doi.org/10.1016/j.neuroscience.2015.08.017
9) Coleshill, M. J., Sharpe, L., Colloca, L., Zachariae, R., & Colagiuri, B. (2018). Placebo andActive Treatment Additivity in Placebo Analgesia: Research to Date and Future Directions.International Review of Neurobiology, 139, 407–441. https://doi.org/10.1016/bs.irn.2018.07.021
10) Dafsari, H. S., Silverdale, M., Strack, M., Rizos, A., Ashkan, K., Mahlstedt, P., Sachse, L.,Steffen, J., Dembek, T. A., Visser-Vandewalle, V., Evans, J., Antonini, A., Martinez-Martin, P., Ray-Chaudhuri, K., & Timmermann, L. (2018). Nonmotor symptoms evolution during 24 months of bilateral subthalamic stimulation in Parkinson’s disease. Movement Disorders, 33(3),421–430. https://doi.org/10.1002/mds.27283
11) Dayal, V., Limousin, P., & Foltynie, T. (2017). Subthalamic Nucleus Deep Brain Stimulation in Parkinson’s Disease: The Effect of Varying Stimulation Parameters. Journal of Parkinson’s Disease, 7(2), 235–245. https://doi.org/10.3233/jpd-171077
12) De La Fuente-Fernández, R., Ruth, T., Sossi, V., Schulzer, M., Calne, D., & Stoessl, A. (2001).Expectation and Dopamine Release: Mechanism of the Placebo Effect in Parkinson’s Disease
.https://employees.csbsju.edu/hjakubowski/classes/medew/pdfs/placebodopamine.pdf
13) Diamond, S. G., Markham, C. H., & Treciokas, L. J. (1985). Double-blind trial of pergolide for Parkinson’s disease. Neurology, 35(3), 291–291. https://doi.org/10.1212/wnl.35.3.291
14) Enck, P., Klosterhalfen, S., & Zipfel, S. (2011). Novel study designs to investigate the placebo response. BMC Medical Research Methodology, 11(1). https://doi.org/10.1186/1471-2288-11-90
15) Espay, A. J., Norris, M. M., Eliassen, J. C., Dwivedi, A., Smith, M. S., Banks, C., Allendorfer, J. B., Lang, A. E., Fleck, D. E., Linke, M. J., & Szaflarski, J. P. (2015). Placebo effect of medication cost in Parkinson disease. Neurology, 84(8), 794–802. https://doi.org/10.1212/WNL.0000000000001282
16) Geers, A. L., Faasse, K., Guevarra, D. A., Clemens, K. S., Helfer, S. G., & Colagiuri, B. (2020).Affect and emotions in placebo and nocebo effects: What do we know so far? Social and Personality Psychology Compass, 15(1). https://doi.org/10.1111/spc3.12575
17) Goetz, C. G., Laska, E., Hicking, C., Damier, P., Müller, T., Nutt, J., Warren Olanow, C., Rascol,O., & Russ, H. (2008). Placebo influences on dyskinesia in Parkinson’s disease. Movement Disorders, 23(5), 700–707. https://doi.org/10.1002/mds.21897
18) Haerling (Adamson), K., & Prion, S. (2020). Two-by-Two Factorial Design. Clinical Simulation in Nursing, 49. https://doi.org/10.1016/j.ecns.2020.06.004
19) Herr, H. W. (2005). Franklin, Lavoisier, and Mesmer: Origin of the controlled clinical trial. Urologic Oncology: Seminars and Original Investigations, 23(5), 346–351.https://doi.org/10.1016/j.urolonc.2005.02.003
20) Hróbjartsson, A., & Gøtzsche, P. C. (2001). Is the Placebo Powerless? New England Journal of Medicine, 344(21), 1594–1602. https://doi.org/10.1056/nejm200105243442106
21) Kerr, P. L., & Gregg, J. M. (2024). The Roles of Endogenous Opioids in Placebo and Nocebo Effects: From Pain to Performance to Prozac. Advances in Neurobiology, 183–220. https://doi.org/10.1007/978-3-031-45493-6_10
22) Levine, J., Gordon, N., & Fields, H. (1978). THE MECHANISM OF PLACEBO ANALGESIA. The Lancet, 312(8091), 654–657. https://doi.org/10.1016/s0140-6736(78)92762-9
23) LeWitt, P. A., & Kim, S. (2015). The pharmacodynamics of placebo: Expectation effects of price as a proxy for efficacy. Neurology, 84(8), 766–767. https://doi.org/10.1212/wnl.0000000000001294
24) Lin, H. Y., Hasegawa, H., Mundil, N., Samuel, M., & Ashkan, K. (2019). Patients’ Expectations and Satisfaction in Subthalamic Nucleus Deep Brain Stimulation for Parkinson Disease: 6-Year Follow-up. World Neurosurgery, 121, e654–e660. https://doi.org/10.1016/j.wneu.2018.09.181
25) Lindheimer, J. B., Szabo, A., Raglin, J. S., & Beedie, C. (2019). Advancing the understanding of placebo effects in psychological outcomes of exercise: Lessons learned and future directions .European Journal of Sport Science, 20(3), 326–337. https://doi.org/10.1080/17461391.2019.1632937
26) Lubejko, S. T., Giulia Livrizzi, Buczynski, S. A., Patel, J., Yung, J. C., Yaksh, T. L., & Banghart, M. R. (2024). Inputs to the locus coeruleus from the periaqueductal gray and rostroventral medulla shape opioid-mediated descending pain modulation. Science Advances, 10(17). https://doi.org/10.1126/sciadv.adj9581
27) Mameli, F., Zirone, E., Girlando, R., Scagliotti, E., Giulia Rigamonti, Edoardo Nicolò Aiello,Poletti, B., Ferrucci, R., Ticozzi, N., Silani, V., Locatelli, M., Barbieri, S., & Ruggiero, F. (2023).Role of expectations in clinical outcomes after deep brain stimulation in patients with Parkinson’s disease: a systematic review. Journal of Neurology, 270(11), 5274–5287. https://doi.org/10.1007/s00415-023-11898-6
28) McGee, C., Liebert, A., Bicknell, B., Pang, V., Isaac, V., McLachlan, C. S., Hosen Kiat, & Herkes, G. (2023). A Randomized Placebo-Controlled Study of a Transcranial Photobiomodulation Helmet in Parkinson’s Disease: Post-Hoc Analysis of Motor Outcomes. Journal of Clinical Medicine, 12(8), 2846–2846. https://doi.org/10.3390/jcm12082846
29) McRae, C., Cherin, E., Yamazaki, T. G., Diem, G., Vo, A. H., Russell, D., Ellgring, J. H., Fahn, S., Greene, P., Dillon, S., Winfield, H., Bjugstad, K. B., & Freed, C. R. (2004). Effects of Perceived Treatment on Quality of Life and Medical Outcomesin a Double-blind Placebo Surgery Trial. Archives of General Psychiatry, 61(4), 412.
https://doi.org/10.1001/archpsyc.61.4.412
30) Meeuwis, S. H., van Middendorp, H., Pacheco-Lopez, G., Ninaber, M. K., Lavrijsen, A. P. M., van der Wee, N., Veldhuijzen, D. S., & Evers, A. W. M. (2019). Antipruritic Placebo Effects by Conditioning H1-antihistamine. Psychosomatic Medicine, 81(9), 841–850. https://doi.org/10.1097/psy.0000000000000743
31) Mehta, N., & Gupta, S. (2024). The Placebo Effect in Dermatology: Managing Patients’ Expectations. Critical Thinking in Contemporary Dermatology: Cognitive Essays, 265–278. https://doi.org/10.1007/978-981-97-0411-8_18
32) Mercado, R., Constantoyannis, C., Mandat, T., Kumar, A., Schulzer, M., Stoessl, A. J., & Honey, C. R. (2006). Expectation and the placebo effect in Parkinson’s disease patients with subthalamic nucleus deep brain stimulation. Movement Disorders, 21(9), 1457–1461. https://doi.org/10.1002/mds.20935
33) Miller, F. G., Colloca, L., & Kaptchuk, T. J. (2009). The Placebo Effect: Illness and Interpersonal Healing. Perspectives in Biology and Medicine, 52(4), 518–539. https://doi.org/10.1353/pbm.0.0115
34) Movement Disorder Society Task Force on Rating Scales for Parkinson’s Disease. (2003). The Unified Parkinson’s Disease Rating Scale (UPDRS): Status and recommendations. Movement Disorders, 18(7), 738–750.
https://doi.org/10.1002/mds.10473
35) Nikoletta Bódi, Szabolcs Kéri, Nagy, H., Moustafa, A. A., Myers, C. E., Daw, N. D., György Dibó, Annamária Takáts, Dániel Bereczki, & Gluck, M. A. (2009). Reward-learning and the novelty-seeking personality: a between- and within-subjects study of the effects of dopamine agonists on young Parkinson’s patients. Brain, 132(9), 2385–2395. https://doi.org/10.1093/brain/awp094
36) Ortega, Á., Salazar, J., Galban, N., Rojas, M., Ariza, D., Chávez-Castillo, M., Nava, M., Riaño-Garzón, M. E., Díaz-Camargo, E. A., Medina-Ortiz, O., & Bermúdez, V. (2022). Psycho-Neuro-Endocrine-Immunological Basis of the Placebo Effect: Potential Applications beyond Pain Therapy. International Journal of Molecular Sciences, 23(8), 4196. https://doi.org/10.3390/ijms23084196
37) Park, H. R., Lim, Y. H., Song, E. J., Lee, J. M., Park, K., Park, K. H., Lee, W.-W., Kim, H.-J., Jeon, B., & Paek, S. H. (2020). Bilateral Subthalamic Nucleus Deep Brain Stimulation under General Anesthesia: Literature Review and Single Center Experience. Journal of Clinical Medicine, 9(9), 3044. https://doi.org/10.3390/jcm9093044
38) Pfaar, O., Agache, I., Bergmann, K., Bindslev‐Jensen, C., Bousquet, J., Creticos, P. S., Devillier, P., Durham, S. R., Hellings, P., Kaul, S., Kleine‐Tebbe, J., Klimek, L., Jacobsen, L., Jutel, M.,Muraro, A., Papadopoulos, N. G., Rief, W., Scadding, G. K., Schedlowski, M., & Shamji, M. H. (2021). Placebo effects in allergen immunotherapy—An EAACI Task Force Position Paper.Allergy, 76(3), 629–647. https://doi.org/10.1111/all.14331
39) Petrovic, P. (2002). Placebo and Opioid Analgesia– Imaging a Shared Neuronal Network.Science, 295(5560), 1737–1740. https://doi.org/10.1126/science.1067176
40) Radomska, M., Flores Alves dos Santos, J., Weber, K., Baertschi, M., Burkhard, P. R., Herrmann, F., Belayachi, S., Favez, N., & Canuto, A. (2022). Assessing preoperative hope and expectations related to functional neurosurgery: a new questionnaire. BMC Psychology, 10(1). https://doi.org/10.1186/s40359-022-00766-z
41) Rémy Boussageon, Howick, J., Baron, R., Florian Naudet, Falissard, B., Ghina Harika-Germaneau, Issa Wassouf, François Gueyffier, Nemat Jaafari, & Blanchard, C. (2022). How do they add up? The interaction between the placebo and treatment effect: A systematic review. British Journal of Clinical Pharmacology (Print), 88(8), 3638–3656. https://doi.org/10.1111/bcp.15345
42) Schmidt, L., Braun, E. K., Wager, T. D., & Shohamy, D. (2014). Mind matters: placebo enhances reward learning in Parkinson’s disease. Nature Neuroscience, 17(12), 1793–1797. https://doi.org/10.1038/nn.3842
43) Seeman, P., Wilson, A., Gmeiner, P., & Kapur, S. (2006). Dopamine D2 and D3 receptors in human putamen, caudate nucleus, and globus pallidus. Synapse, 60(3), 205–211. https://doi.org/10.1002/syn.20298
44) Shetty, N., Friedman, J. H., Kieburtz, K., Marshall, F. J., & Oakes, D. (1999). The placebo response in Parkinson’s disease. Parkinson Study Group. Clinical Neuropharmacology, 22(4),207–212. https://pubmed.ncbi.nlm.nih.gov/10442249/
45) Skvortsova, A., Veldhuijzen, D. S., Kloosterman, I. E. M., Meijer, O. C., van Middendorp, H., Pacheco-Lopez, G., & Evers, A. W. M. (2019). Conditioned hormonal responses: A systematic review in animals and humans. Frontiers in Neuroendocrinology, 52, 206–218. https://doi.org/10.1016/j.yfrne.2018.12.005
46) Staessen, J. A., Fagard, R., Thijs, L., Celis, H., Arabidze, G. G., Birkenhäger, W. H., Bulpitt, C. J., de Leeuw, P. W., Dollery, C. T., Fletcher, A. E., Forette, F., Leonetti, G., Nachev, C., O’ Brien, E. T., Rosenfeld, J., Rodicio, J. L., Tuomilehto, J., & Zanchetti, A. (1997). Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Lancet, 350(9080), 757–764. https://doi.org/10.1016/s0140-6736(97)05381-6
47) Tallarida, R. J. (2001). Drug synergism: its detection and applications. The Journal of Pharmacology and Experimental Therapeutics, 298(3), 865–872. https://pubmed.ncbi.nlm.nih.gov/11504778/
48) Tinoco, F. A., Hughes, T. E. S., Robertson, R. V., Crawford, L., Meylakh, N., Macey, P. M., Macefield, V. G., Keay, K. A., & Henderson, L. A. (2023). Detailed organisation of the human midbrain periaqueductal grey revealed using ultra-high field magnetic resonance imaging.NeuroImage, 266, 119828–119828. https://doi.org/10.1016/j.neuroimage.2022.119828
49) Tresker, S. (2022). Consciousness, Placebo Effects, and the Therapeutic Allure of Psychoneuroimmunology. Perspectives in Biology and Medicine, 65(1), 1–24. https://doi.org/10.1353/pbm.2022.0000
50) Vollert, J., Cook, N. R., Kaptchuk, T. J., Sehra, S. T., Tobias, D. K., & Hall, K. T. (2020). Assessment of Placebo Response in Objective and Subjective Outcome Measures in Rheumatoid Arthritis Clinical Trials. JAMA Network Open, 3(9), e2013196–e2013196. https://doi.org/10.1001/jamanetworkopen.2020.13196
51) Wager, T. D., & Atlas, L. Y. (2015). The neuroscience of placebo effects: connecting context, learning and health. Nature Reviews Neuroscience, 16(7), 403–418. https://doi.org/10.1038/nrn3976
52) Wilhelm, M., Winkler, A., Rief, W., & Doering, B. K. (2016). Effect of placebo groups on blood pressure in hypertension: a meta-analysis of beta-blocker trials. Journal of the American Society of Hypertension, 10(12), 917–929. https://doi.org/10.1016/j.jash.2016.10.009
53) Willoch, F., Rosen, G., Tölle, T. R., Oye, I., Wester, H. J., Berner, N., Schwaiger, M., & Bartenstein, P. (2000). Phantom limb pain in the human brain: unraveling neural circuitries of phantom limb sensations using positron emission tomography. Annals of Neurology, 48(6),842–849. https://pubmed.ncbi.nlm.nih.gov/11117540/
54) Wilson-Poe, A. R., Wiese, B., Kibaly, C., Lueptow, L., Garcia, J., Anand, P., Cahill, C., & Morón, J. A. (2021). Effects of inflammatory pain on CB1 receptor in the midbrain periaqueductal gray. PAIN Reports, 6(1), e897. https://doi.org/10.1097/pr9.0000000000000897
55) Ziesche, P. (2022). Containing the Flow of Animal Magnetism: Benjamin Franklin, Thomas Jefferson, John Adams, and the Mesmer Report. Transactions of the American Philosophical Society, 110(2), 295–311.
https://www.jstor.org/stable/45400915
56) Zubieta, J.-K., & Stohler, C. S. (2009). Neurobiological Mechanisms of Placebo Responses. Annals of the New York Academy of Sciences, 1156(1), 198–210.https://doi.org/10.1111/j.1749-6632.2009.04424.x